Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis [PDF]
Open Veterinary Journal, 2022 Background: Hyperinsulinemia associated with pituitary pars intermedia dysfunction (PPID) and/or equine metabolic syndrome (EMS) is well documented to put horses at high risk of laminitis.
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Gut microbial carbohydrate metabolism contributes to insulin resistance
Nature, 2023 Faecal carbohydrates, particularly host-accessible monosaccharides, are increased in individuals with insulin resistance and are associated with microbial carbohydrate metabolisms and host inflammatory cytokines.
T. Takeuchi +24 more
semanticscholar +1 more source
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
Open Veterinary Journal, 2023 Background: Sodium-Glucose CoTransporter-2 [SGLT2] inhibitors, the -flozin group of drugs, which block glucose reuptake in the renal proximal tubule, are being increasingly used off-label to treat horses with refractory hyperinsulinemia. After two years
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Possible dysmetabolic hyperferritinemia in hyperinsulinemic horses [PDF]
Open Veterinary Journal, 2019 Background: Hyperinsulinemia associated with equine metabolic syndrome (EMS) and pituitary pars intermedia dysfunction (PPID) is a risk factor for laminitis.
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Signal Transduction and Targeted Therapy, 2022 The centenary of insulin discovery represents an important opportunity to transform diabetes from a fatal diagnosis into a medically manageable chronic condition.
Mengwei Li +5 more
semanticscholar +1 more source
Insulin Resistance: From Mechanisms to Therapeutic Strategies
Diabetes & Metabolism Journal, 2021 Insulin resistance is the pivotal pathogenic component of many metabolic diseases, including type 2 diabetes mellitus, and is defined as a state of reduced responsiveness of insulin-targeting tissues to physiological levels of insulin.
Shin-Hae Lee, Shi-Young Park, C. Choi
semanticscholar +1 more source
Clinical analysis of insulin resistance in liver cirrhosis patients
Shanghai Jiaotong Daxue xuebao. Yixue ban, 2023 Objective·To investigate the insulin resistance in liver cirrhosis patients.Methods·Patients with liver cirrhosis from Xinhua Hospital,Shanghai Jiao Tong University School of Medicine in 2013‒2017 were retrospectively assessed.
SHI Cuicui +4 more
doaj +1 more source
DMRT2 Interacts With FXR and Improves Insulin Resistance in Adipocytes and a Mouse Model
Frontiers in Endocrinology, 2022 Insulin resistance (IR) plays a critical role in cardiovascular diseases and metabolic diseases. In this study, we identified the downregulation of DMRT2 in adipose tissues from insulin-resistant subjects through bioinformatics analysis and in an insulin-
Jing Tao +11 more
doaj +1 more source
Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain. [PDF]
PLoS ONE, 2016 OBJECTIVES:Our aim was to investigate if genetic variations in the visfatin gene (SNPs rs7789066/ rs11977021/rs4730153) could modify the cardiovascular-risk (CV-risk) despite the metabolic phenotype (obesity and glucose tolerance).
María Teresa Martínez Larrad +6 more
doaj +1 more source
Myths about Insulin Resistance: Tribute to Gerald Reaven [PDF]
Endocrinology and Metabolism, 2019 Gerald Reaven was often called the “father of insulin resistance.” On the 1-year anniversary of his death in 2018, we challenge three myths associated with insulin resistance: metformin improves insulin resistance; measurement of waist circumference ...
Sun H. Kim, Fahim Abbasi
doaj +1 more source